[go: up one dir, main page]

AR062786A1 - Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos. - Google Patents

Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.

Info

Publication number
AR062786A1
AR062786A1 ARP070104060A ARP070104060A AR062786A1 AR 062786 A1 AR062786 A1 AR 062786A1 AR P070104060 A ARP070104060 A AR P070104060A AR P070104060 A ARP070104060 A AR P070104060A AR 062786 A1 AR062786 A1 AR 062786A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
alkyl
benzoxasols
preparation
disposed
Prior art date
Application number
ARP070104060A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062786(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR062786A1 publication Critical patent/AR062786A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de los mismos -solos o en combinacion con uno o más compuestos farmacéuticamente activos diferentes- para el tratamiento en especial de una enfermedad mediada por la cinasa de proteína tirosina (tal como una enfermedad tumoral) o para la fabricacion de una preparacion farmacéutica para utilizarse en el tratamiento de esta enfermedad. Reivindicacion 1: Un compuesto de la formula (1) en donde X es N o CR5; en donde R5 es halogeno, ciano, hidroxilo, alcoxilo C1-7, alquilo C1-7, amino, N-mono- o N,N-di-alquilo C1-7 o de preferencia H; R1 es arilo insustituido o sustituido o es heterociclilo insustituido o sustituido; y R2 es arilo insustituido o sustituido o es heterociclilo insustituido o sustituido, el cual está enlazado por medio de un átomo de C del anillo; R3 es ciano, hidroxilo, alquilo C1-7, amino, N-mono- o N,N-di-alquilo C1-7 o de preferencia H; y R4 es hidroxilo, amino o de preferencia H; o sales del mismo.
ARP070104060A 2006-09-15 2007-09-13 Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos. AR062786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors

Publications (1)

Publication Number Publication Date
AR062786A1 true AR062786A1 (es) 2008-12-03

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104060A AR062786A1 (es) 2006-09-15 2007-09-13 Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.

Country Status (30)

Country Link
US (1) US8629168B2 (es)
EP (2) EP1900729A1 (es)
JP (1) JP5325105B2 (es)
KR (1) KR20090064389A (es)
CN (1) CN101516860B (es)
AR (1) AR062786A1 (es)
AT (1) ATE532774T1 (es)
AU (1) AU2007296916B2 (es)
BR (1) BRPI0716841A2 (es)
CA (1) CA2660987A1 (es)
CL (1) CL2007002669A1 (es)
CO (1) CO6150142A2 (es)
CR (1) CR10639A (es)
EA (1) EA200900388A1 (es)
ES (1) ES2377148T3 (es)
GT (1) GT200900056A (es)
IL (1) IL196860A0 (es)
MA (1) MA30723B1 (es)
MX (1) MX2009002812A (es)
NO (1) NO20091469L (es)
PA (1) PA8748101A1 (es)
PE (1) PE20080842A1 (es)
PL (1) PL2066647T3 (es)
PT (1) PT2066647E (es)
SM (1) SMP200900023B (es)
TN (1) TN2009000070A1 (es)
TW (1) TW200819444A (es)
UY (1) UY30587A1 (es)
WO (1) WO2008031594A1 (es)
ZA (1) ZA200900477B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
AU2009270511B2 (en) * 2008-07-15 2013-07-18 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
AR073010A1 (es) * 2008-08-12 2010-10-06 Takeda Pharmaceutical Compuesto amida con actividad agonista del gpr52
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2745004C (en) 2008-11-28 2014-07-15 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
UY33176A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2, 5, 7.
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
BR112016017997A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Beta aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
WO2015117146A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
EP3331851A1 (en) 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053479B (en) * 1999-12-10 2005-03-25 Pfizer Prod Inc Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
BRPI0615449A2 (pt) * 2005-09-02 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst do subtipo 5 e uso desses compostos
WO2008009458A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
SMP200900023B (it) 2009-07-14
PL2066647T3 (pl) 2012-04-30
CN101516860B (zh) 2012-06-27
MA30723B1 (fr) 2009-09-01
NO20091469L (no) 2009-04-15
EA200900388A1 (ru) 2009-08-28
ES2377148T3 (es) 2012-03-22
UY30587A1 (es) 2008-05-02
CO6150142A2 (es) 2010-04-20
TN2009000070A1 (en) 2010-08-19
JP2010503629A (ja) 2010-02-04
JP5325105B2 (ja) 2013-10-23
PA8748101A1 (es) 2009-08-26
US8629168B2 (en) 2014-01-14
PE20080842A1 (es) 2008-08-11
PT2066647E (pt) 2012-01-17
TW200819444A (en) 2008-05-01
IL196860A0 (en) 2009-11-18
CL2007002669A1 (es) 2008-05-09
ZA200900477B (en) 2010-01-27
AU2007296916B2 (en) 2011-10-06
ATE532774T1 (de) 2011-11-15
CA2660987A1 (en) 2008-03-20
EP1900729A1 (en) 2008-03-19
AU2007296916A1 (en) 2008-03-20
CN101516860A (zh) 2009-08-26
CR10639A (es) 2009-07-03
US20100009978A1 (en) 2010-01-14
WO2008031594A1 (en) 2008-03-20
SMAP200900023A (it) 2009-05-11
KR20090064389A (ko) 2009-06-18
GT200900056A (es) 2011-11-08
MX2009002812A (es) 2009-03-31
BRPI0716841A2 (pt) 2013-10-01
EP2066647A1 (en) 2009-06-10
EP2066647B1 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
AR062786A1 (es) Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
GT200500221A (es) Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR066014A1 (es) Difenil- dihidro -imidazopiridinonas. composiciones farmaceuticas y usos.
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
ECSP10010722A (es) Compuestos orgánicos
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
UY29705A1 (es) " inhibidores macrocíclicos del virus de la hepatitis c"
EA200970047A1 (ru) Водные суспензии тмс278
CL2008002130A1 (es) Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
CL2010000667A1 (es) Compuestos derivados de ciclohexil-piperazinil-metanona, antagonistas y/o agonistas inverso h3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de la obesidad, diabetes tipo ii y dislipidemia (sol. div. 60-07).
UY29301A1 (es) Derivados amida

Legal Events

Date Code Title Description
FB Suspension of granting procedure